AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 281 min read$UTHR

ROTHBLATT MARTINE A sold $4.5M of UTHR (indirect holdings)

ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $476.17 ($470.56–$478.95, $4.52M total) across 9 trades on 2026-09-25 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · ROTHBLATT MARTINE A
Published Sep 28, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 29, 2026, 2:48 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$UTHR
Bearish
high confidence
Mentioned
$UTHR
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$UTHRBearishLow
01

Why it matters

The disclosed sale adds new information about insider holdings, potentially influencing short‑term sentiment.

02

Market read

First‑report insider sale provides fresh data for traders; may trigger modest bearish moves in UTHR.

03

What to watch

No immediate catalyst beyond the filing; broader market trends may dominate price movement.

Relevance 5/10Novelty 4/10Timing: post‑market today

Background

Form 4 filings disclose insider transactions; a 10b5‑1 plan indicates pre‑planned sales, reducing speculation about motive.

Company-level read

Ticker impact

$UTHRBearishHigh confidence
Context

CEO Martine A. Rothblatt sold $4.5M of United Therapeutics shares via a 10b5-1 plan, reducing her stake to 324,443 shares.

Expected impact

likely downward pressure as the market prices in the insider sell.

Evidence & confidence

A senior executive's open-market sale of nearly 10,000 shares at $476 average is a material transaction for a mid‑cap biotech, often interpreted as a negative signal.

Market effects

Sector

Biotech sector may see modest sell pressure from insider activity.

Regional

US market, primarily affecting Nasdaq‑listed biotech stocks.

Global

Limited global impact; relevance confined to UTHR investors.

Counterpoint

What could challenge this read

The sale could be purely portfolio rebalancing under a pre‑arranged 10b5‑1 plan, not a lack of confidence.

Key entities

  • company
    United Therapeutics Corp

    NASDAQ‑listed biotech focused on pulmonary and transplant therapies.

  • person
    Martine A. Rothblatt

    Chairperson & CEO of United Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

UTHR insider trading history →

Related articles

OCT 28
$UTHRMed

United Therapeutics Receives FDA Clearance to Begin Clinical Trial of Inhaled PAH Treatment

United Therapeutics (UTHR) received FDA clearance to start clinical trials for Treprostinil-Iloprost SMI, an inhaled treatment for pulmonary arterial hypertension (PAH). The phase 1 trial will assess safety and tolerability. The therapy aims to address symptom flare-ups between maintenance doses. UTHR plans a phase 2 trial in 2027 if initial results are positive. PAH affects around 500,000 people globally.

finance.yahoo.com2 min
OCT 28
$UTHRMed

FDA clears a trial of a two-drug inhaler that could be the first as-needed therapy for lung artery disease.

The FDA approved a trial for Treprostinil-Iloprost SMI, a potential first as-needed inhaler therapy for pulmonary arterial hypertension (PAH). United Therapeutics plans a phase 1 study in 2026, with a phase 2 study in PAH patients anticipated in 2027. The therapy combines treprostinil and iloprost, aiming to provide episodic symptom relief. United Therapeutics aims to expand its PAH treatment portfolio.

stocktitan.net2 min